INTRODUCTIONThe human immunodeficiency virus (HIV) has infected more than 75 million people around the world over the years (Deeks et al. 2015). According to estimates published in 2024 by the World Health Organization (WHO), the total number of people living with HIV corresponds to 39.9 million people, with 38.6 million of those infected being adults and of these, 20.5 million infected people are women, which represents more than 50% of the total infected population. The WHO also describes that the number of people acquiring HIV each year is estimated at 1.3 million people, so it is necessary to establish preventive methods to reduce the acquisition of HIV (WHO, 2024).For the prevention of HIV, an effective mechanism is the pre-exposure prophylaxis (PrEP) in which through a daily dose of the medication called Truvada (tenofovir disoproxil fumarate/emtricitabine), can help to reduce the acquisition of HIV infection, when combined with safe sex practices, the drug was approved in 2012 by the U. S. Food and Drug Administration (FDA). The drug was approved in 2012 by the U.S. Food and Drug Administration (FDA) and is now one of the main tools for preventing HIV infection over the years, being released for use by all subpopulations at risk of infection (Kamitani et al. 2024; FDA, 2012).It is important to emphasize that even though protocols and guidelines have been in place for over 12 years, even with the intense use of oral medication and more recently with the use of injectable PrEP, there is still a lack of inclusion of some subgroups in a more effective way (CDC, 2024). It is currently known that the groups of men who have sex with men (MSM), sex workers and transgender people represent the subpopulations most at risk of HIV infection. However, analyzing the timeline, the data shows that women represent more than half of all those infected over the years and there is also the fact that there is not much research related to cisgender women, the use of PrEP and their adherence to the drug (Nozza et al. 2022).For cisgender women and their subgroups to adhere to PrEP, there are several known barriers and disadvantages, such as society’s stigma towards these women, the lack of effective communication between health professionals and patients, campaigns and advertisements that are not very effective, discrimination, among other problems that prevent women from achieving greater adherence to PrEP and, in turn, more research is required to understand all the factors that are linked to these barriers (Devlin et al. 2023). Given the lack of focus and specificity regarding cisgender women and the fact that adherence to PrEP is not widely known, this scoping review aims to understand PrEP adherence and its effective implementation in high-risk populations, specifically women.